Detecting the epidermal growth factor receptors status in non-small cell lung cancer

Chinese Medical Journal

Volumn 124, Issue 24, 2011, Pages 4324-4329

  Meng, Xue ^a   Yu, Jin Ming ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Epidermal growth factor receptors; Lung cancer; Molecular imaging

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; CARBON 11; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; GEFITINIB; MESSENGER RNA;

ADVANCED CANCER; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CHEMOSENSITIVITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; DNA SEQUENCE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MECHANISM; DRUG RESPONSE; DRUG TUMOR LEVEL; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; GENE ACTIVATION; GENE DOSAGE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RECEPTOR GENE; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84862938368     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.24.035     Document Type: Article

References (32)

1. Schiller JH, Harrington D, Belani CP. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346: 92-98.
2. Patel JD, Pasche B, Argiris A. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. Crit Rev Oncol Hematol 2004; 50: 175-186.
3. Dei Tos AP, Ellis I. Assessing epidermal growth factor receptor expression in tumors: what is the value of current test methods? Eur J Cancer 2005; 41: 1383-1392.
4. Miller VA. EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer. Semin Oncol Nurs 2008; 24: 27-33.
5. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol 2004; 22: 3238-3247.
6. Lynch TJ, Bell DW, Sordella R, Gurubhagavatual S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
7. Paez JG, Janne PA, Lee JC, Greulich H, Gabriel S, Herman P, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
8. Rafael R, Teresa M, Felipe C, Rut P, Santiago V, Miguel A, et al. Predictive biomarkers in the management of EGFR mutant lung cancer. Ann N Y Acad Sci 2010; 1210: 45-52.
9. Zhu YJ, Xia Y Ren GJ, Wang MZ, Zheng X, Zhang L. Efficacy and clinical/molecular predictors of erlobinib monotherapy for Chinese advanced non-small cell lung cancer. Chin Med J 2010; 123: 3200-3205.
10. Gazdar AF, Shigematsu H, Herz J, Minna JD. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med 2004; 10: 481-486.
11. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M, et al. Oncogenic transformation by inhibitor-sensitive and resistant EGFR mutants. PLosS Med 2005; 2: e313.
12. Cappuzzo F. EGFR FISH versus mutation: different tests, different end-points. Lung Cancer 2008; 60: 160-165.
13. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2005; 97: 643-655.
14. Vollebergh MA, Kappers I, Klomp HM, Buning-Kager JC, Korse CM, Hanptmann M, et al. Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010; 5: 1939-1948.
15. Tsao DA, Yang MJ, Chang HJ, Yen LC, Chiu HH, Hsueh EJ, et al. A fast and convenient new technique to detect the therapeutic target, K-ras mutant, from peripheral blood in non-small cell lung cancer patients. Lung cancer 2010; 68: 51-57.
16. Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small cell lung cancer. J Clin Onc 2009; 27: 2653-2659.
17. Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, Tamori S, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 2007; 97: 778-784.
18. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008; 14: 985-990.
19. Shepherd FA, Pereira J, Ciuleanu TE. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. Proc Am Soc Clin Onc 2004; 22: 7022.
20. Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 2007; 58: 95-103.
21. Oriuchi N, Higuchi T, Ishikita T, Miyakubo M, Hanaoka H, Iida Y et al. Present role and future prospects of positron emission tomography in clinical oncology. Cancer Sci 2006; 97: 1291-1297.
22. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004; 231: 305-332.
23. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-1782.
24. 18F-FDG uptake and EGFR mutation in patients with non-small cell lung cancer: a single-institution retrospective analysis. Lung Cancer 2010; 67: 76-80.
25. Sunaga N, Oriuchi N, Kaira K, Yanagitani N, Tomizawa Y, Hisada T et al. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer 2008; 59: 203-210.
26. Smith SV. Molecular imaging with copper-64. J Inorg Biochem 2004; 98: 1874-1901.
27. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005; 23: 1137-1146.
28. Wang JQ, Gao M, Miller KD, Sledge GW, Zheng QH. Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem Lett 2006; 16: 4102-4106.
29. 11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res 2009; 69; 873-878.
30. Wang H, Yu JM, Yang GR. Further characterization of the epidermal growth factor receptor ligand 11C-PD153035. Chin Med J 2007; 120: 960-964.
31. 11C-PD153035 in humans. J Nucl Med 2009; 50: 303-308.
32. 11C-PD153035 PET/CT for molecular imaging of EGFR in patients with non-small cell lung cancer. J Clin Oncol 2008; 26 Suppl: 3503.